Clinical Trial 51292

Tulsa, OK 74137


This is a Phase 2, randomized, double-blind, parallel-group, placebo-controlled, dose-ranging, multicenter study to evaluate the safety and efficacy of lutikizumab in adult subjects with moderate to severe HS who have failed anti-TNF therapy.

The study is comprised of a 35-day Screening Period, a 16-week double-blind placebo-controlled Treatment Period, and a 9-week Follow-Up Period (10 weeks after the last dose of study drug).

Qualified Participants Must:

• Have a diagnosis of Hidradenitis Suppurativa
• Have Failed Anti-TNF Therapy (Humira, Cimzia, or Enbrel)

Qualified Participants May Receive:

All Study related procedures and office visits with a board certified dermatologist at no charge. 

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.